Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 182
- 试验地点
- 2
- 主要终点
- Neuroimaging
研究概览
简要总结
Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. We would like to examine how obstructive sleep apnea may contribute to the progression of Alzheimer's disease.
详细描述
Aim 1: We will assess the endotypes (mechanisms) underlying OSA in elderly individuals known to be high risk for AD (vs. non-OSA matched controls) using novel recently validated simplified techniques which do not require burdensome complex overnight experiments to assess endotypes (primary outcome loop gain). We will further assess the predicted response to O2 therapy in terms of respiratory outcomes among elderly OSA patients with varying levels of loop gain and pharyngeal collapsibility.
Hypothesis 1: A substantial proportion of high AD risk patients with OSA should be O2 responsive as predicted using pathophysiological assessments.
Aim 2: We will perform an overnight mechanistic study of oxygen therapy vs. room air in high AD risk patients with OSA (recruited from Aim 1 and others if necessary). Given the frequent intolerance of PAP in elderly patients, we anticipate that oxygen therapy may be a viable therapeutic approach in this fragile population. We will focus on respiratory outcomes (primary outcome: apnea hypopnea index) but also assess sleep dependent memory consolidation on word pairs task given the major impact in the elderly.
Hypothesis 2: O2, compared to room air, will improve OSA and neurocognitive outcomes in select elderly OSA patients at risk of AD.
Aim 3: Preclinical AD with OSA and non-OSA controls, from Aim 1 will have structural and molecular brain imaging focusing on hippocampal atrophy as a predictor of memory consolidation. We will also assess amyloid and tau in the medial temporal region as function of OSA severity and as a predictor of neurocognitive function. This aim will lay the groundwork for designing a robust clinical trial using neuroimaging outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
If subjects have been randomized to receive room air, subjects will have a nasal cannula with pressurized room air to avoid unblinding.
入排标准
- 年龄范围
- 65 Years 至 85 Years(Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 65-85 years
- •Gender: Men or Women
- •Independently living and able to drive
- •OSA (AHI ≥ 15/h) or no OSA
- •Subjects must consent to waiving their right to obtain their PHS score (since the score is not yet actionable and could lead to social stress and ethical dilemmas)
排除标准
- •Currently smoking
- •History of COPD or asthma
- •Heart Failure Class III or IV, unstable cardiovascular disease, or uncontrolled hypertension
- •Neuromuscular Disease
- •Drowsy Driving (ESS > 18/24)
- •Inability to complete study procedures, such as questionnaire that are only available/validated in English
- •Lack of decisional capacity to provide informed consent
- •Participants in whom magnetic resonance imaging Magnetic Resonance Imaging [MRI] is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant
- •Presence of a brain tumor or lobar stroke
- •Current drug or alcohol abuse/dependence
研究组 & 干预措施
Supplemental Oxygen during PSG
Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
干预措施: Supplemental Oxygen (Other)
PAP Therapy for 3 Months
Over a 12-week period, participants randomized to receive supplemental PAP therapy for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
干预措施: Continuous Positive Airway Pressure Machine (Device)
Room Air during PSG
Subjects will be instrumented with a nasal cannula to receive 2L/min of pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
干预措施: Room Air (Other)
Supplemental Oxygen for 3 Months
Over a 12-week period, participants randomized to receive supplemental Oxygen for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
干预措施: Supplemental Oxygen (Other)
结局指标
主要结局
Neuroimaging
时间窗: 2 hours
MRI and PET Scans. This study will examine pre-clinical AD with OSA patients using brain imaging (structural MRI and amyloid/tau PET). MRI will be conducted to provide a structural image suitable for coregistering the PET image and observing white matter integrity. The scan should take 35 minutes. These will be MPRAGE images collected using the standard ADNI protocol at the in-house 3T MRI scanner at the UCSD Altman Clinical and Translational Research Institute (ACTRI). The PET scan should take 70-90 minutes.
Loop Gain (LG)
时间窗: 8 hours
A method used to measure respiratory stability of the negative feedback chemoreflex control system using a specialized Positive Airway Pressure machine called a pCrit. The overall loop gain of the ventilatory system reflects the ratio of the ventilatory response to the disturbance that elicited the response (LG = ventilatory response/ventilatory disturbance). The higher the loop gain, the potentially more unstable the respiratory control system becomes.
Apnea Hypopnea Index
时间窗: 8 hours
The number of times a person stops breathing and periods of shallow breathing with a marked decrease in blood oxygen concentration every hour on average. A score lower than five indicates normal sleep (no sleep apnea), 5-15 indicates mild sleep apnea, 15-30 indicates moderate sleep apnea, and a score greater than 30 indicates severe sleep apnea.
次要结局
- Pittsburg Sleep Quality Index (PSQI)(12 weeks)
- Insomnia Severity Index (ISI)(12 weeks)
- Epworth Sleepiness Scale (ESS)(12 weeks)
研究者
Atul Malhotra
Professor, Medicine
University of California, San Diego
